ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Massachusetts General Hospital at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Massachusetts General Hospital takes part in 8 sessions at ESMO 2026 in Madrid. Its work spans treatment and tumor biology in lung, breast, head and neck, and gastrointestinal cancers. It examines ordastobart with pembrolizumab as initial treatment for recurrent or metastatic head and neck cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Massachusetts General Hospital Boston, MA | |
Teaching hospital of Harvard Medical School in Boston, Massachusetts, with a cancer centre. | Poster Fri Oct 23 13:00–15:00 Immune-molecular phenotypes and therapeutic surface antigen expression in nasopharyngeal carcinoma Sarcoma, CNS, head & neck and rare cancers Satellite Fri Oct 23 18:20–18:40 Satellite Fri Oct 23 18:40–19:00 Advances in 1L therapy for metastatic NSCLC: Current and emerging biomarkers and treatment strategies Lung & thoracic cancersBiomarkers & precision oncology Satellite Fri Oct 23 19:40–19:45 Close Breast cancer Abstract Sun Oct 25 08:30–08:40 LBA42 - HexAgon-HN: A phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1– high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) - Phase 2 primary analysis Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 09:00 Poster Sun Oct 25 12:00–12:45 Abstract Mon Oct 26 08:50–09:02 Invited Discussant LBA69, 2615O Lung & thoracic cancers Satellite Mon Oct 26 13:10–13:30 |
Find decision makers at Massachusetts General Hospital
Tell us what you sell and we’ll find the people at Massachusetts General Hospital most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction